Serological assays to measure dimeric IgA antibodies in SARS‐CoV‐2 infections
Authors:
- Zihui WeiZWZihui Wei
- Fiona AngrisanoFAFiona Angrisano
- Emily M ErikssonEEEmily M Eriksson
- Ramin MazhariRMRamin Mazhari
- Huy VanHVHuy Van
- Rob J CenterRCRob J Center
- Irene BooIBIrene Boo
- James McMahonJMJames McMahon
- Jillian LauJLJillian Lau
- Nicholas Kiernan‐WalkerNKNicholas Kiernan‐Walker
- Shazia Ruybal‐PesántezSRShazia Ruybal‐Pesántez
Open Access
- 18 August 2023
- journal article
- research article
- Published by Wiley in Immunology & Cell Biology
- Vol. 101 (9) , 857-866
Abstract
Current serological tests cannot differentiate between total immunoglobulin A (IgA) and dimeric IgA (dIgA) associated with mucosal immunity. Here, we describe two new assays, dIgA‐ELISA and dIgA‐multiplex bead assay (MBA), that utilize the preferential binding of dIgA to a chimeric form of secretory component, allowing the differentiation between dIgA and monomeric IgA. dIgA responses elicited through severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection were measured in (i) a longitudinal panel, consisting of 74 samples (n = 20 individuals) from hospitalized cases of coronavirus disease 2019 (COVID‐19); (ii) a longitudinal panel, consisting of 96 samples (n = 10 individuals) from individuals with mild COVID‐19; (iii) a cross‐sectional panel with PCR‐confirmed SARS‐CoV‐2 infection with mild COVID‐19 (n = 199) and (iv) pre–COVID‐19 samples (n = 200). The dIgA‐ELISA and dIgA‐MBA demonstrated a specificity for dIgA of 99% and 98.5%, respectively. Analysis of dIgA responses in the longitudinal panels revealed that 70% (ELISA) and 50% (MBA) of patients elicited a dIgA response by day 20 after PCR diagnosis with a SARS‐CoV‐2 infection. Individuals with mild COVID‐19 displayed increased levels of dIgA within the first 3 weeks after diagnosis but responses appeared to be short lived, compared with sustained IgA levels. However, in samples from hospitalized patients with COVID‐19 we observed high and sustained levels of dIgA, up to 245 days after PCR diagnosis. Our results suggest that severe COVID‐19 infections are associated with sustained levels of plasma dIgA compared with mild cases.Keywords
Funding Information
- Impact Fund (IPAP2022/0456)
- National Health and Medical Research Council (1116530)
This publication has 19 references indexed in Scilit:
- How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretionsInfluenza and Other Respiratory Viruses, 2019
- Detection of virus-specific polymeric immunoglobulin A in acute hepatitis A, C, E virus serum samples using novel chimeric secretory componentBMC Research Notes, 2018
- Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humansVaccine, 2014
- Multi-Faceted Functions of Secretory IgA at Mucosal SurfacesFrontiers in Immunology, 2013
- Secretory IgA's complex roles in immunity and mucosal homeostasis in the gutMucosal Immunology, 2011
- Selective IgA DeficiencyJournal of Clinical Immunology, 2010
- The Carboxyl-terminal Domains of IgA and IgM Direct Isotype-specific Polymerization and Interaction with the Polymeric Immunoglobulin ReceptorJournal of Biological Chemistry, 2002
- Fine Specificity of Ligand-Binding Domain 1 in the Polymeric Ig Receptor: Importance of the CDR2-Containing Region for IgM InteractionThe Journal of Immunology, 1999
- Disulfide bond formation between dimeric immunoglobulin A and the polymeric immunoglobulin receptor during hepatic transcytosis†Hepatology, 1994
- High serum levels of secretory IgA in liver diseaseDigestive Diseases and Sciences, 1982